Contract Research & Services
Clinical Trials

Clinical Trials News

View news from other Pharmaceutical sectors:
436-450 of 4332 results
ProQR's QR-010 proof of concept CF study meets primary endpoint
ProQR Therapeutics announced that clinical study PQ-010-002, a proof-of-concept study of nasal potential difference (NPD), demonstrated that QR-010 restored CFTR function in a cohort of homozygous ∆F508 cystic fibrosis (CF) patients.
Contract Research & Services > Clinical Trials > News
FDA places partial hold on AstraZeneca’s two cancer drug trials
By PBR Staff Writer
The US Food and Drug Administration (FDA) has placed a partial clinical hold on AstraZeneca’s two cancer drug trials over bleeding incidents.
Contract Research & Services > Clinical Trials > News
Boehringer Ingelheim's Humira biosimilar candidate succeeds in rheumatoid arthritis study
By PBR Staff Writer
Boehringer Ingelheim’s adalimumab biosimilar candidate has demonstrated similar efficacy and safety profile to AbbVie’s Humira in pivotal phase III study in patients with active rheumatoid arthritis (RA).
Contract Research & Services > Clinical Trials > News
OncoGenex unveils positive survival results from Apatorsen phase 2 trial in metastatic bladder cancer
OncoGenex Pharmaceuticals has unveiled positive survival results from the final analysis of the Phase 2 Borealis-2 trial of apatorsen in combination with docetaxel treatment that enrolled 200 patients with metastatic bladder cancer whose disease had progressed following first-line platinum-based chemotherapy.
Contract Research & Services > Clinical Trials > News
Daiichi Sankyo selects anti-HER3 monoclonal antibody Patritumab for I-SPY 2 trial in breast cancer
Daiichi Sankyo and QuantumLeap Healthcare Collaborative announced that a new treatment arm of the I-SPY2 TRIAL will include patritumab, an investigational anti-HER3 monoclonal antibody.
Contract Research & Services > Clinical Trials > News
Lexicon reports positive results in phase 2 dose-ranging study for Sotagliflozin in type 1 diabetes
Lexicon Pharmaceuticals said that the Phase 2 dose-ranging, inTandem4 clinical trial of dual SGLT1 and SGLT2 inhibitor sotagliflozin met its primary endpoint, showing a statistically significant reduction in A1C at 12 weeks in patients with type 1 diabetes.
Contract Research & Services > Clinical Trials > News
AstraZeneca’s Lynparza shows significant PFS benefit in ovarian cancer patients
By PBR Staff Writer
A phase III trial designed to evaluate the efficacy of AstraZeneca’s Lynparza (olaparib) tablets as maintenance treatment for women with BRCA-mutated metastatic ovarian cancer has demonstrated significant progression-free survival (PFS) benefit.
Contract Research & Services > Clinical Trials > News
Global Blood Therapeutics to start phase 3 study for GBT440 in sickle cell disease
By PBR Staff Writer
Global Blood Therapeutics (GBT) will start a phase 3 clinical trial in December for GBT440 in adults and adolescents with sickle cell disease (SCD).
Contract Research & Services > Clinical Trials > News
Merck’s Keytruda meets primary endpoint in urothelial cancer study
By PKBR Staff Writer
A phase 3 study evaluating the use of Merck’s Keytruda (pembrolizumab) immunotherapy in patients with previously treated advanced urothelial cancer, met the primary endpoint of overall survival (OS).
Contract Research & Services > Clinical Trials > News
Amgen's Xgeva matches zoledronic acid in phase 3 trial in multiple myeloma-related bone complications
By PBR Staff Writer
A phase 3 study assessing Amgen’s Xgeva (denosumab) compared to zoledronic acid (ZA) for the prevention of bone complications in newly diagnosed multiple myeloma (MM) patients met its primary endpoint.
Contract Research & Services > Clinical Trials > News
Sanifit starts first clinical trial of SNF472 in patients with calciphylaxis
Laboratoris Sanifit has started the first clinical trial of its lead candidate, SNF472, for the treatment of the orphan disease calciphylaxis (calcific uraemic arteriolopathy, CUA).
Contract Research & Services > Clinical Trials > News
Theravance and Mylan’s COPD treatment shows benefits in phase 3 trials
By PBR Staff Writer
A drug that is being developed by Theravance Biopharma and Mylan has shown promise in two phase 3 efficacy studies treating patients with chronic obstructive pulmonary disease.
Contract Research & Services > Clinical Trials > News
Merck's letermovir succeeds in preventing CMV infection in phase 3 study
A phase 3 clinical trial evaluating Merck's letermovir for prevention of cytomegalovirus (CMV) infection in high-risk bone marrow transplant patients, met its primary endpoint.
Contract Research & Services > Clinical Trials > News
Eiger doses first patient in phase 2 LIMT HDV study
Eiger BioPharmaceuticals has dosed the first patient in the Phase 2 LIMT HDV (Lambda Interferon MonoTherapy in HDV) study, a monotherapy trial of pegylated interferon lambda 1a (Lambda) as a potential treatment for chronic hepatitis D virus (HDV) infection.
Contract Research & Services > Clinical Trials > News
LLS launches collaborative clinical trial for acute myeloid leukemia
The Leukemia & Lymphoma Society (LLS) has launched a collaborative clinical trial for acute myeloid leukemia (AML), a deadly disease which has seen few improvements in treatments in over 40 years.
Contract Research & Services > Clinical Trials > News
436-450 of 4332 results